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Abstract 
Pharmaceuticals are ubiquitous in the natural environment with concentrations expected to 
rise as human population increases. Environmental risk assessments are available for a small portion 
of pharmaceuticals in use, raising concerns over the potential risks posed by other drugs that have 
little or no data. With >1900 active pharmaceutical ingredients in use, it would be a major task to 
test all of the compounds with little or no data. Desk-based prioritization studies provide a potential 
solution by identifying those substances that are likely to pose the greatest risk to the environment 
and which therefore need to be considered a priority for further study. The aim of this review was to 
(1) employ different prioritization methodologies used for pharmaceuticals in the environment and 
the results generated and (2) propose a new holistic risk-based prioritization framework for drugs in 
the environment. Suggested models to underpin this framework are discussed in terms of validity 
and applicability. The availability of data required to run the models was assessed and data gaps 
identified for future research needs. The implementation of this framework may harmonize 
pharmaceutical prioritization efforts and indicate that in the future, experimental resources might   
focused on molecules, endpoints and environmental compartments that are biologically relevant.  
Keywords: Active pharmaceutical ingredient, Prioritization, Environmental risk assessment, Exposure 
modelling, Effects prediction 
 
Introduction 
Pharmaceuticals are an invaluable commodity to society; their use enables greater quality and 
longevity of life. Extensive patient and veterinary use, incomplete metabolism, continuous use by 
society, and lack of rapid biodegradability of many active pharmaceutical ingredients (APIs) resulted 
in their ubiquitous presence in various environmental media (Redshaw et al. 2013; Gaw and Brooks 
2016; Bergheim et al. 2014), and detection in non-target organisms (Miller et al. 2015; Tanoue et al. 
2015; Cuthbert et al. 2014). Pharmaceuticals can reach the environment via multiple point source 
and diffuse pathways including incomplete removal in conventional wastewater treatment and 
subsequent release into surface waters (Luo et al. 2014); release of untreated wastewater directly or 
through combined sewer overflows (CSOs) (Mennigen et al. 2011; Phillips et al. 2012); migration in 
landfill leachate (Masoner et al. 2016); agricultural use and sludge spreading (Mohapatra et al. 
2016); domestic septic tank discharge (Yang et al. 2016); and release of manufacturing effluent 
(Cardoso et al. 2014; Larsson 2014).  
Environmental monitoring studies detected 631 pharmaceuticals in 71 countries (aus der Beek 
et al. 2016), with these monitoring campaigns reporting concentrations in the aquatic environment 
typically at low µg/L to sub-ng/L levels (Batt et al. 2017; Singer et al. 2016). Despite the low 
concentrations, this widespread occurrence of pharmaceuticals in the environment has led to 
concerns over their potential impacts due to their known biological activity in various species 
including fish, amphibians, and humans which indicates that non-target organisms are affected 
(Ankley et al. 2007; Mennigen et al. 2011; Brodin et al. 2017). Environmental effects of 
pharmaceuticals have been documented in wildlife (Oaks et al. 2004; Scholz and Klüver 2009; 
Weatherly and Gosse 2017) and potential effects suspected in human populations; however further 
research is required to demonstrate this (Wang et al. 2016). An increasing, ageing population, rising 
welfare standards and projected elevation in global populations within a progressively urbanized 
environment (United Nations, 2014), is expected to result in increased use of pharmaceutical , which 
might amplify existing concentrations of compounds in environmental media and, potentially, 
associated risks for some specific drugs for which there is a low margin of safety (MOS), or site-
specific risks where high population densities and low dilution occurs. Recent projections suggest 
that pharmaceutical usage in the UK alone might double by 2052 (Royal Commission on 
Environmental Pollution, 2011). On the other hand, (1) improved preventative health measures, (2) 
development of green or biologically-based pharmaceuticals, or (3) increased oral absorption might 
reduce environmental input loads (Straub 2016), while improved wastewater treatment (Itzel et al, 
2017) or increased access to sanitation might also mitigate environmental and non-therapeutic 
human exposure in future. 
An environmental risk assessment (ERA) is required as part of the marketing authorization 
process for new APIs in the European Union and United States. In the European Union, the European 
Medicines Agency (EMA) has implemented an ERA process for human medicinal products registered 
after 2006. Detailed criticism of this process is outside the scope of this review; however, many 
limitations were identified (BIO Intelligence Service 2013; Pereira et al. 2017). Specifically, trigger 
values to assess environmental compartments beyond the aquatic assessment may not be sufficient 
to catch risks in the current ERA process. EMA based ERAs were only conducted for a small 
proportion of the APIs currently granted market authorization (Datapharm Communications Limited 
2017). An analysis of the availability of European Public Assessment Reports (EPARs) from the EMA 
(2017) for the top 350 pharmaceuticals in use in the UK, demonstrates that ERA data were available 
for only 71 of these molecules (Supplementary Material). High volume use pharmaceuticals such as 
paracetamol, carbamazepine, or amoxicillin, all commonly cited in the literature as high priority 
compounds possess no publicly available EMA ERA. Other regional ERA initiatives exist such as 
^ǁĞĚĞŶ ?Ɛ tŝŬŝƉŚĂƌŵĂ (MistraPharma, 2018). These assessments may not be directly comparable, 
but if pooled into a new central database might be a more effective tool for identifying which ERA 
data are currently available and where significant data gaps exist for specific APIs or specific 
mechanisms of action (BIO Intelligence Service, 2013). 
The difference between number of pharmaceuticals currently authorized for market use and 
those with environmental data is therefore large (Figure 1). Potentially, those substances with little 
or no environmental data may pose risks. To conduct full ERAs on all pre-2006 authorized 
pharmaceuticals would be a substantial and likely unnecessary task, as the majority of currently 
assessed pharmaceuticals demonstrate a good MOS with studies focused in Europe predicting that 
approximately 5-10% of drugs in use might pose any appreciable risk to the environment (Roos et al. 
2012; Küster and Adler 2014). Therefore it would be valuable to identify those pharmaceuticals most 
likely to pose the greatest risk then assess these through targeted experimental testing and 
environmental monitoring. Desk-based prioritization approaches which screen pharmaceuticals 
based upon either hazard, exposure, or risk might help as they may be utilized to focus monitoring 
campaigns, effects testing, or decide which pharmaceuticals most urgently require a tailored ERA 
(Boxall et al. 2012). The use of such approaches might help ensure that APIs of potential concern are 
identified and tested while minimizing unnecessary organism testing and not compromising testing 
of novel APIs by saturating environmental testing capacity in contract research organizations.  
A variety of prioritization approaches were suggested, which employ different methodologies 
(Dong et al. 2013; Kumar and Xagoraraki 2010; Diamond et al. 2011; Besse et al 2012; Fick et al. 
2010; Ortiz de García et al. 2013, Guo et al. 2016). Many of these approaches are limited in scope in 
terms of both number of compounds included and environmental exposure routes considered. The 
reason for this might be due to lack of suitable models currently available to explore environmental 
exposure beyond freshwater aquatic compartments. Currently, prioritization approaches are 
generally employed to inform monitoring campaigns or select compounds to undertake effects 
research. The number of pharmaceuticals currently missing an ERA and those for which there are 
data might be limited in terms of endpoints/environmental compartments considered, indicating 
risks may be missed. This presents another opportunity for pharmaceutical prioritization, to inform 
the ERA process.  
The aim of this critical review was to develop an optimal prioritization framework that might 
be applied to various understudied exposure scenarios and regions of the world, to serve as a guide 
to researchers, industry, and regulators, whilst highlighting which investigations specifically are 
needed to address knowledge gaps prior to implementation of the framework. The development of 
the optimal  prioritization framework was achieved through the following objectives: to i) identify 
the variability of prioritized pharmaceuticals geographically, thereby helping to determine the scale 
at which the optimal prioritization needs to be undertaken, ii) collate previous pharmaceutical 
prioritization results to identify which approach was most balanced, iii) based upon this approach, 
evaluate the strengths and weaknesses and identify opportunities for improvement, and iv) develop 
a framework based upon the selected prioritization approach and evaluate the models which might 
underpin the approach in terms of validity and suitability for pharmaceuticals.  
To address these goals, a systematic literature search of the Web of Science and Scopus® 
databases as well as the Google Scholar search engine was conducted, using combinations of the 
ŬĞǇǁŽƌĚƐ  ‘ƉŚĂƌŵĂĐĞƵƚŝĐĂů ? ǁŝƚŚ ĞŝƚŚĞƌ  ‘prioritization ? ?  ‘ƌĂŶŬŝŶŐ ? Žƌ  ‘ƉƌŝŽƌŝƚǇ ? ? ĚĚŝƚŝŽŶĂů ƚĂƌŐĞƚĞĚ
searching was included where appropriate from identified literature references. Prioritization 
exercises and risk assessments that either identified a pharmaceutical of concern or several priority 
compounds were included. A total of 73 papers were identified, several of which included multiple 
priority lists (total 76) either representing different environmental compartments or prioritization 
approaches. References are reported in the Supplemental Material. To limit the scope, only human 
pharmaceutical usage is considered. Pharmaceutical mixtures, while gaining significant attention in 
terms of pharmaceutical risk assessment, are beyond the scope of the framework currently. Finally, 
as this is a review, an optimal prioritization framework is presented; further research required to 
ultimately implement this framework is outlined. 
Previous prioritization approaches 
Geographical spread 
In total, 76 prioritization exercises were identified covering 24 countries (Figure 2). Multiple 
prioritization exercises were performed in the USA, France, Switzerland and Sweden. In each of 
these countries, prioritization exercises used a variety of approaches including risk, hazard or 
exposure (see General approaches section) and were both generic and country-specific (e.g. via local 
usage data). The most common approach for countries in which a single prioritization was 
undertaken is risk-based such as combined exposure and effects. Regional differences in priority 
compounds suggests that risks are regionally specific, likely driven by the existence of national 
marketing authorization approaches, pharmaceutical costs, prescribing practices, disease pressures, 
wastewater treatment and connectivity, and climatic or hydrological conditions, all of which affect 
exposure and therefore potential risk posed by particular compounds (Figure 2). This is an important 
consideration and suggests that a prioritization result from one geographical region may not be 
suitable for another location. While the majority of pharmaceutical prioritizations focused in Europe 
and USA, and to a lesser extent Asia, the remainder of the world is scarcely covered (Figure 2). These 
understudied areas might be harboring hot spots of pharmaceutical exposure and risk, due for 
example to environmental inputs from pharmaceutical manufacturing and formulation sites with 
inadequate effluent treatment (Larsson 2014), large urban populations such as India, Brazil or 
Nigeria or the fact that many of these regions have limited or no sewage treatment connectivity.  
General Approaches 
 Different prioritization approaches used globally may be characterized into three general 
categories: exposure-based; hazard-based and risk-based. These approaches are discussed in more 
detail below. 
Exposure-based methods 
Exposure-based methods prioritize pharmaceuticals solely based upon predictions or 
measurements of compound concentrations in the environment. In general, this type of approach is 
utilized to develop monitoring campaigns by selecting pharmaceuticals most likely to be present, 
thereby focusing on costly monitoring efforts (Kim et al. 2006; Riva et al. 2015; Götz et al. 2010).  The 
greater the pharmaceutical usage, the higher the load that is expected to reach the environment and 
therefore the greater the priority score (Riva et al. 2015). To prioritize based upon predicted 
exposure, simple predicted environmental concentrations (PECs) are calculated using approaches 
such as that defined by the EMA (2006), Equation 1. 
3(& 0DVV)H[FUHWD-::73UHPRYDO::LQKDELWDQWV(QYLURQPHQWDOGLOXWLRQ                                          [1] 
Pharmaceutical consumption (Mass) per capita (µg/person·day) is estimated based upon sales 
or prescription data. The Fexcretra term is patient excretion, derived from peer-reviewed 
pharmacokinetic studies of the compound. . Wastewater treatment plant (WWTP) removal is either 
predicted utilizing quantitative structure activity relationships (QSARs), for example the STPWIN 
program (which predicts removal of a chemical in a typical conventional activated sludge WWTP), 
ƉĂƌƚ ŽĨ ƚŚĞ h^W ?Ɛ W/^h/d ƐŽĨƚǁĂƌĞ ƉĂĐŬĂŐĞ which estimates the environmental fate of a 
molecule using physico-chemical properties (US Environmental Protection Agency 2015) or based 
upon measured values previously reported in the literature. WWTP removal may be assumed to be 
zero to reflect the worst case exposure scenario (Le Corre et al. 2012). The numerator (i.e. the 
predicted pharmaceutical load) is diluted based upon mean amount of wastewater generated per 
person served by the WWTP (WWinhab); the EMA (2006) suggests a default value of 200 L/per 
person·day, although Henze and Comeau (2008) suggest 50 to 400 L/per person·day reflects the 
range in actual water usage practices throughout the world. The EMA (2006) default environmental 
dilution factor is 10, which a global study of dilution factors of WWTP effluent indicating suitability  
for assessing risk (Keller et al. 2014).  
Exposure-based prioritizations may also be based upon measured environmental 
concentrations (MECs). Exposure-based prioritizations offer a means of overcoming limited 
ecotoxicological knowledge of pharmaceuticals by placing a greater focus on what is continually 
entering and present in the environment (Götz et al. 2010; Castiglioni et al. 2006).  
Hazard-based methods 
A small number of pharmaceutical prioritizations identify priority compounds based upon 
their hazard properties. Hazard-based approaches are unbiased by environmental occurrence and 
therefore indicate compounds that display the potential to be harmful based upon potency and/ or 
their mechanism(s) of action such as synthetic hormones or anti-cancer drugs. These might be 
missed in some risk-based methods (Christen et al. 2010), or exposure-based methods which 
intentionally focus on high-use drugs, compounds of known environmental presence, or which lack 
exposure data. Hazard-based methods might also be useful for informing pharmaceutical 
substitution policies as part of a risk mitigation measure (Larsson 2014). Generally, hazard-based 
methods identify and score pharmaceuticals based upon their persistence, bioaccumulation, and 
toxicity (PBT) (Fàbrega et al. 2013; Ortiz de García et al. 2013; Wennmalm and Gunnarsson 2005) or 
simply their persistence and bioaccumulation (P&B) (Howard and Muir 2011). These data are usually 
obtained from systems such as ƚŚĞ hŶŝƚĞĚ ^ƚĂƚĞƐ h^W ?Ɛ Wd WƌŽĨŝůĞƌ Žƌ W/^Ƶŝte software 
programs: BIOWIN, BCFBAF and ECOSAR (US Environmental Protection Agency 2015; Environmental 
Health Analysis Center 2016). 
Hazard-based prioritization might also involve  ‘ƌĞĂĚ-ĂĐƌŽƐƐ ? ĨƌŽŵ ƌĞĂĚŝůǇ ĂǀĂŝůĂďůĞ
pharmacokinetic data (Lalone et al. 2014). This leveraging of parameters derived during drug 
development processes enables a consistent comparison across all pharmaceuticals instead of 
biasing the prioritization towards data rich or poor compounds. The absorption, distribution, 
metabolism and excretion (ADME) of substances has been correlated with how a pharmaceutical 
might behave in an organism and therefore the likelihood of causing an adverse effect in the 
environment (Berninger et al. 2016; Lalone et al. 2014). A simpler  ‘ƌĞĂĚ-ĂĐƌŽƐƐ ?approach assumes 
that the plasma concentration of a drug that produces a therapeutic response in a human, might 
potentially induce an effect in a fish at similar plasma concentrations (Huggett et al. 2003). The 
lower the environmental concentration required to reach this concentration in a fish, the higher the 
priority (Fick et al. 2010; Roos et al. 2012). These simpler  ‘ƌĞĂĚ-ĂĐƌŽƐƐ ?ŚĂǌĂƌĚ-based methods not 
based upon ADME parameters, rely on predicting internal organism concentrations based upon the 
bioconcentration factor (BCF) of a compound. While these approaches attempt to overcome heavy 
dependence on predicted PBT data to select priority compounds, their validity as indicators of 
hazard has yet to be extensively assessed and validated. 
Risk-based methods 
The majority of prioritization methods and exercises reported in the literature are risk-based, 
where a measure of risk resulting from the ratio of exposure to effect is ranked by decreasing 
severity (Kools et al. 2008). By placing effects or hazards in the context of environmental occurrence, 
resources are focused not just on detectable or hazardous pharmaceuticals, but those present at a 
concentration likely to result in an appreciable risk. Previous critical assessments of prioritization 
methods concluded that risk-based approaches are most appropriate for prioritizing 
pharmaceuticals (Roos et al. 2012; Caldwell et al. 2014). 
The most common approach to risk-based prioritization is to calculate a risk-quotient (RQ), 
Equation 2. The PEC may be calculated according to Eqn. 1, while the predicted no-effect 
concentration (PNEC) may be extrapolated from the most sensitive ecotoxicological endpoint by 
adjustment with a safety factor, depending upon the source, coverage and nature of the ecotoxicity 
data such as measured or predicted, endpoint reported, acute or chronic to help ensure risks are not 
missed (Guo et al. 2016). These safety factors are based upon assessment factors, which are applied 
to derive a PNEC for an ERA based on the quantity of ecotoxicity data available, outlined by 
regulatory bodies such as the EMA (2006) and US Food and Drug Administration (1998). Similarly to 
PBT hazard-based methods, ecotoxicity data employed in many risk-based prioritization studies are 
often derived from QSAR models such as ECOSAR (Dong et al. 2013), again placing a heavy reliance 
on predictive rather than experimental methods. 
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 Other risk-based methods focused on assessment of risks to predators or humans posed by 
secondary poisoning via exposure from food or water. In the case of human unintended exposure, 
the acceptable daily intake (ADI) is typically used to derive the PNEC (Cunningham et al. 2009; 
Murray et al.  ? ? ? ? ?>ĞƵŶŐĞƚĂů ? ? ? ? ? Z ?KƚŚĞƌĂƉƉƌŽĂĐŚĞƐ ‘ƌĞĂĚ-ĂĐƌŽƐƐ ?ĨƌŽŵƉŚĂƌŵĂĐŽŬŝŶĞƚŝĐĚĂƚĂƚŽ
make ecotoxicological predictions (Huggett et al. 2003; Kostich and Lazorchak 2008). Some risk-
based studies included risks to mammals and humans in addition to the aquatic ecotoxicological 
endpoints frequently considered such as fish, invertebrate, and algae, but rely heavily on predicted 
data (Guo et al. 2016) or complex weighting schemes to deliver rankings (Dong et al. 2013; Guo et al. 
2016; Kumar and Xagoraraki 2010).  
Similar to exposure-based prioritizations, risk-based prioritizations rely on either MECs (Li et 
al. 2014; Morais et al. 2014), PECs (Perazzolo et al. 2010), or a mixture of the two (Roos et al. 2012). 
These PECs and MECs are generally applied to entire countries or regions (Guo et al. 2016). Higher-
tier spatial PEC modelling approaches might also be used. These models digitize the river network 
within a GIS framework to generate spatially refined PECs, such as PhATE (US) and GREAT-ER (EU) 
models (Cunningham et al. 2009; Feijtel et al. 1997). Spatial PECs are achieved by allocating WWTPs, 
their characteristics (population served and WWTP technology), and discharges spatially into the 
river network, while accounting for mixing with pharmaceuticals transported from upstream, to 
make exposure predictions for large-scale river basins (Alder et al. 2010). Oldenkamp et al. (2013) 
refined this concept further by creating a smaller-scale screening tool for Europe capable of deriving 
potential pharmaceutical environmental hotspots. The model generates emissions aggregated into 
100 km x 100 km grids and also includes environmental fate considerations such as hydrolysis, 
biodegradation, photolysis, partitioning to sediment, and releases to soils, based on the SimpleBox 
model (Hollander et al. 2007).  
Prioritization results and current limitations 
Which pharmaceutical classes are most commonly prioritized? 
In total, 332 pharmaceuticals were identified as a priority in the 76 prioritization exercises. 
There were 197 compounds identified only once, while 76 pharmaceuticals were selected as priority 
compounds by three or more exercises. In Table 1, the 76 pharmaceuticals prioritized 3 or more 
times are categorized by prioritization approach, then by therapeutic class. A marked difference may 
be seen in the dominant therapeutic classes selected based upon type of prioritization approach 
employed (Table 1), a similar conclusion to that reached by Roos et al. (2012). 
 Our findings support the findings that potent low-dose pharmaceuticals or those with 
generally higher limits of detections, or both, such as hormones, are completely overlooked by 
purely environmental exposure-based methods.  
The top three therapeutic classes flagged by risk-based approaches are antibiotics (16) 
followed by hormones (10) and analgesics (9). When exposure-based prioritization systems were 
evaluated, antibiotics (10) comprised the largest therapeutic class followed by analgesics (5) and 
lipid-lowering agents (4). Hormones were not selected in any of the exposure-based exercises 
despite their prevalence in hazard- and risk-based prioritization methods. This is expected because 
hormones are potent and administered in small doses, which, despite prevalent usage, results in low 
environmental inputs in terms of mass. Therefore, these compounds are less likely to be detected in 
the environment than their higher mass use counterparts such as antibiotics and analgesics. On the 
other hand, antibiotics and analgesics are prevalent in exposure-based priority lists, similar to risk-
based priorities, indicating that their associated risks may be related to high exposures in mass 
terms.  
Hazard-based methods identified hormones (9) followed by antidepressants (6), cardio-
vascular agents (5) and antibiotics (5) as pharmaceutical classes of highest priority. Analgesics were 
less of a priority according to these approaches, despite their prevalence in risk-based and exposure-
based prioritization outcomes, again indicating that the perceived risks of analgesics are more likely 
a result of high exposure than potency. Antidepressants were the fourth most highly selected 
therapeutic class in risk-based studies and second in hazard-based investigations, but again 
overlooked almost entirely by exposure-based approaches.  
This analysis indicates that prioritizations relying solely on hazard- or exposure-based 
approaches might be misleading, as key therapeutic classes of known environmental risk, whether 
they be hormones or analgesics, were under-represented in comparison to risk-based methods.   
Data are currently not available to determine the accuracy of risk-based approaches which are also 
flawed as these are reliant on combinations of PECs and MECs for exposure, and predicted or 
empirical data for effects. Research efforts need to focus on increasing the certainty in exposure and 
effects approaches to be employed in a reliable prioritization approach, for example validation of 
exposure models through targeted environmental monitoring or validation of ecotoxicity QSARs and 
 ‘read-across ? theories for a range of pharmaceuticals with differing physico-chemical characteristics 
and modes of action. Despite this, the balance between exposure and hazard with a risk-based 
approach is likely the most effective approach for prioritization (Roos et al. 2012; Caldwell et al. 
2014).  
What drives priority compound selection? 
The most common top priority pharmaceuticals were diclofenac and ethinylestradiol (EE2), 
designated as priority compounds in 36% of reviewed priority lists or 26 and 25 times respectively 
(Figure 3). This is predictable considering the substantial focus on these two compounds in the 
literature, documented environmental effects, and their inclusion on the Water Framework Directive 
(WFD) watch list (Negrao de Carvalho et al. 2015). Risk-based methods dominate priority compound 
selection (Figure 3) due to the greater number of studies using this approach (78%), while hazard- 
and exposure-based make up 12 and 9% of prioritizations, respectively. Of the entire list of identified 
pharmaceutical priorities (n=332), which represents roughly 17% of drugs in use, only 17 compounds 
were selected by all three method types. Forty-six were selected by both hazard- and risk-based 
methods or by both exposure- and risk-based methods. Risk-based methods identified 96% of the 
pharmaceuticals in Figure 3, while hazard- and exposure-based methods identified 49 and 45% 
respectively. Clemastine and etonogestrel were identified exclusively by hazard-based methods. 
Whilst identifying those drugs that are selected most often indicates that these might constitute   
the highest risk pharmaceuticals, the driving factor behind these selections is uncertain. It seems to 
be equally driven by hazard and exposure, which is a similar conclusion to that drawn when results 
were grouped by therapeutic class. 
Limitations and opportunities with current methodologies 
Prioritization methodologies have differing goals, whether it is deciding on which 
pharmaceuticals to conduct standard or non-standard effects testing, environmental monitoring, 
selecting legacy compounds for a targeted ERA, or underpinning risk management options. Many 
different variations of the three main prioritization approaches were undertaken suggesting that 
consensus on a suitable method has yet to be reached. Based upon collated previous prioritization 
results, exposure- and hazard-based approaches likely overlook pharmaceuticals that may pose a 
potential risk. It was therefore concluded that the use of risk-based approaches for prioritization is 
preferable. While several risk-based methods are available, these employ different approaches. 
Some used experimental monitoring data while others utilized exposure predictions. Some use 
toxicity  ‘read-across ? approaches while others employ QSARs developed for general chemicals.  
Table 2 highlights the strengths, limitations, threats and opportunities of different approaches that 
were employed previously for risk-based prioritization of pharmaceuticals.  
In terms of exposure (Table 2), it is evident that relying upon monitoring data limits the 
number of compounds than might be considered to those already present in the environment or a 
small fraction of drugs in use. Prioritization based upon MECs may be skewed by methodological 
limitations including: limited number of detections, analytical detection limits, compounds 
considered, or the risks being overstated by using maximal MECs (Vazquez-Roig et al. 2012; Pereira 
et al. 2016). Therefore prioritizations dependent upon MECs may not be sufficiently comprehensive 
to provide meaningful results to risk assessors (Caldwell et al. 2014). Conversely, a simple PEC (based 
on the EMA (2006) approach) permits inclusion of a larger range of compounds in a prioritization, 
however PECs are complicated by a lack of, or variability in, parameters required to calculate them. 
Access to regionally defined usage data is important, but sometimes difficult to obtain or does not 
capture all relevant usage pathways. Over-the-counter (OTC) pharmaceutical usage might be missed 
by prescription-based usage, while sales data might overlook generic formulations. The public 
availability of prescription, hospital, and OTC pharmaceutical sales data is uncommon and generally 
only available at the national or regional scale, which may not be representative of localized 
conditions. In most countries/regions, pharmaceutical consumption datasets are only available 
through expensive market research. To overcome this, calculations of per capita drug usage might 
be estimated similar to an approach used recently in a prioritization in Kazakhstan where usage 
estimates were based upon the number of products available for each active ingredient utilized in 
the country (Aubakirova et al. 2017). This accuracy of this method is unknown, as it has yet to be 
validated against monitoring data.  
Another difficulty encountered is the diversity in patient metabolism estimations, 
compounded with the variability in WWTP removal efficiency along with potential of conjugated 
metabolites such as glucuronide or sulfato-conjugates to reform the active parent compound due to 
cleavage of the conjugate during water treatment processes (Burns et al. 2017). Environmental 
dilution exhibits substantial spatial and temporal variability, which is another significant source of 
uncertainty. The impact of local dilution variability on simple PECs was investigated by Verlicchi 
(2014) and estimated to produce an uncertainty of up to 695%. Environmental fate is generally 
overlooked which includes dissipation processes such as biodegradation and partitioning to sludge 
and sediment, both of which affect exposure estimates and potentially prioritization rankings 
(Booker et al. 2014; Huber et al. 2016). Further, simple PECs are limited to single source systems 
such as a single WWTP on a river with no upstream contribution, which is not a frequent scenario. 
Higher-tier spatial models provide an opportunity to move past these limited simple PECs by 
incorporating multiple pharmaceutical sources and upstream contributions along with in-stream fate 
to generate spatially relevant PECs. Inclusion of all these factors to derive localized concentrations 
may be necessary to manage risk at the local/regional level (Gardner et al. 2013), as prioritization 
results were found to be influenced by localized conditions as well as by the scale at which the 
exercise is undertaken (e.g. European Union, country, or locally) (Oldenkamp et al. 2016).  
In terms of the PNEC (Table 2), experimental ecotoxicity data for pharmaceuticals is limited 
and to compensate for this, models are extensively utilized which may be inappropriate for all or for 
specific groups of pharmaceuticals and/or have yet to be validated for drugs specifically. ECOSAR 
was commonly cited as the source of modelled ecotoxicity data despite many compounds falling 
outside its applicability domain (Dong et al. 2013; Guo et al. 2016; Ortiz de García et al. 2013). In 
addition, the relevance to pharmaceuticals is questionable as ECOSAR was originally validated using 
a small set of industrial chemicals with simple molecular structures dissimilar to those of drugs and 
mainly acting via a non-specific narcosis mode of action (Sangion and Gramatica 2016; Sanderson et 
al. 2004). Further, non-specific narcosis and apical acute toxicity endpoints such as endpoints related 
to growth, reproduction and mortality used for ERAs, are likely to occur at concentrations higher 
than those arising through chronic exposure as these conditions do not reflect low level continuous 
exposure. Chronic experimental data derived for ERAs, while more suitable for risk assessment than 
acute data, still focuses on apical endpoints and therefore might also be missing key effects related 
to the intended mode of action (MoA) of the pharmaceutical (Ankley et al. 2007; Brausch et al. 
2012). Therefore a prioritization approach which captures MoA-based concerns concomitant with 
apical endpoints, need to be incorporated into a prioritization framework aimed at informing risk 
assessment monitoring and testing strategies to ensure these potential risks are not overlooked. 
Although the results of the reviewed prioritizations are useful; there are several general scope 
limitations that potentially diminish confidence in the findings. Certain prioritization approaches 
remove pharmaceuticals that lack relevant experimental data (Stuer-Lauridsen et al. 2000; Jones et 
al. 2002; Besse et al. 2008), thus a criticism of prioritization is that it continually prioritizes 
pharmaceuticals that have already been examined; the phenomenon is termed the  ‘Matthew Effect ? 
(Daughton 2014). Suitable models, which are validated and may be applied across physico-
chemically diverse range of pharmaceuticals are required to overcome this limitation. All 
prioritizations reviewed considered a single pharmaceutical source to the environment, WWTP 
discharge. Many compounds are manufactured in countries such as India or China, where 
investigations showed manufacturing effluent reached concentrations of 237 mg/L in production 
heavy regions, leading to localized pharmaceutical hot spots (Cardoso et al. 2014; Lübbert et al. 
2017; Larsson 2014). Moreover, while less manufacturing is done in Europe and North America, 
increased pharmaceutical loads in surface water due to manufacturing were documented at 
concentrations 30-500-fold higher than those in unaffected areas (Phillips et al. 2010), highligting the 
fact that this is a global consideration. Not considering these sources may thus markedly 
underestimate risks and therefore identification of priority compounds (Larsson 2014).  
The main focus of the reviewed prioritizations was on a single environmental compartment, 
surface water. The reason for limiting the scope to surface water might be a current lack of validated 
exposure models suitable for predicting concentrations in other relevant environmental 
compartments such as sediments, biosolids, soils and porewater. Only three prioritizations included 
or focused on the sediment compartment (Al-Khazrajy and Boxall 2016; Olsen et al. 2013; Casado-
Martinez et al. 2017). Another exposure pathway overlooked in the vast majority of reviewed 
approaches is the application of biosolids (Guo et al. 2016) and reclaimed irrigation waters (Lees et 
al. 2016) to agricultural fields. Agricultural soil exposure is derived from sludge concentrations of 
pharmaceuticals in WWTPs, which is the result of sorption characterized by the sludge/water 
partition coefficient (Kd) (Berthod et al. 2017). Most sorption models are driven by hydrophobicity 
(i.e. logKow > 4), however many pharmaceuticals are ionizable at environmentally relevant pH 
values and Pan et al. (2009) demonstrated that sorption is also affected by ionic state. Therefore 
models that estimate sorption and do not consider the ionic state of a compound may be unreliable; 
an example is the commonly used STPWIN model (US Environmental Protection Agency 2015), as 
estimates of pharmaceuticals in both WWTP sludge and the aquatic environment may be 
over/underestimated (Dong et al. 2013; Sanderson et al. 2004). Models that do include ionic state 
considerations (e.g. SimpleTreat 4.0) are thus preferred.  
The absence of ecotoxicity data or validated ecotoxicity models available, is another factor 
which may have contributed to the scope of reviewed prioritizations encapsulating only the water 
column. There is evidence that drugs were detected in invertebrate organisms in benthos and soil 
(Grabicova et al. 2015; Heye et al. 2016; Karlsson et al. 2016; Kinney et al. 2008); therefore, risks to 
these compartments needs to be considered. In addition, potential risks to predators and humans 
have, with a few exceptions (Murray-Smith et al. 2012; Guo et al. 2016), been overlooked, despite 
recent findings to suggest that these risks may be present (Wang et al. 2016; Mottaleb et al. 2016; 
Franklin et al. 2016; Malchi et al. 2014; Oaks et al. 2004). Therefore, several opportunities to 
improve prioritization exist, such as including understudied environmental pathways and 
compartments, diet and food chain assessments for predators, pharmaceutical sources beyond the 
WWTP, and inclusion of MoA-based concerns concomitant with apical ecotoxicological effects data. 
The following section brings together the strengths of existing methods and attempt to overcome 
current limitations in scope to develop an optimal prioritization framework which may be used in 
the future for pharmaceutical prioritization. 
Proposed prioritization framework 
The proposed prioritization methodology uses a tiered, risk-based approach. The method is 
holistic in that it: (1) considers all relevant environmental compartments; (2) assesses specific risks 
to plants, invertebrates, vertebrates and mammals (human and non-human) as well as incorporating 
food chain interactions; and (3) considers endpoints related to MoA, in addition to apical acute and 
chronic ecotoxicological endpoints of a pharmaceutical. It is based upon models capable of 
leveraging existing data to overcome bias towards data-rich or -poor pharmaceuticals when 
generating risk ranks. The framework also accounts for differences in pathways of exposure for 
different regions as well as variations in the drivers of exposure such as differences in water 
chemistry which affect compound uptake and equilibrium partitioning. The framework will be 
underpinned by thorough model validation and defined applicability domains to yield greater 
confidence in results whilst highlighting current weaknesses and knowledge gaps. In the future, the 
overall approach needs to be validated against both lab and field data to demonstrate it is a reliable 
tool in pharmaceutical prioritization.  
Navigating the Framework 
The starting point and progression through the framework is dependent upon the question 
being asked, which generally falls into one of 4 main categories: i) Identifying highest risk 
pharmaceuticals from the approximately 1900 APIs in use to determine which are in greatest need 
of targeted relevant effects testing or ERAs, ii) developing a catchment-scale or national monitoring 
campaign to determine the status of predicted risks in the real world, iii) identifying compounds 
posing a risk at regional or local scales, for effects research based upon predicted effects data, or iv) 
identifying risk mitigation measures that aim to minimize the mass of an API reaching the 
environment, for example risk-benefit analysis, WWTP upgrades, reductions of incorrect disposal, 
increased pharmaceutical bioavailability, or incorporation into legislation such as the WFD.  
The acquisition of relevant pharmaceutical consumption data is critical to progressing through 
the exposure component of the framework regardless of the research question (Figure 4). Despite 
the shortcomings of PECs and difficulties in obtaining accurate consumption data, these should still 
be favored for prioritization over a MEC, to ensure a wider range of pharmaceuticals is considered 
and potent drugs with high analytical limits of detection are not overlooked. Effluents from 
pharmaceutical manufacturing facilities need to be treated using a tailored approach, as many 
compounds are produced through batch production producing transient pharmaceutical hot spots, 
in contrast to low level continuous therapeutic use. Manufacturing PECs require knowledge of 
industrial manufacturing schedules, batch production and a mass balance of pharmaceutical 
recovery and losses (Murray-Smith et al. 2012) paired with localized effluent and environmental 
dilution. In the case of hospitals treating and releasing their own effluent, these sources also need to 
be accounted for. In addition to the sources, interactions between environmental compartments 
also need to be considered, including re-partitioning between pore water and sediment/soil as well 
as between these solid phases and surface water.  
A limitation with the framework is pharmaceutical sources currently not considered because 
their impacts are expected to be minimal or localized, such as septic systems, CSOs, animal 
husbandry, aquiculture and landfills. There are currently no apparent models available to 
incorporate these pathways; however, as such models become available these need to be 
incorporated into the framework. Further, spatial and temporal variations in pharmaceutical usage 
and environmental conditions might impact the accuracy of exposure predictions. Higher-tier spatial 
exposure models are most desirable to accommodate spatial variability; however, these are 
currently only available for certain regions. When not available, the scale at which a prioritization is 
conducted dictates whether EMA (2006) suggested defaults (Supplementary Material) for 
parameters such as environmental dilution are most suitable (e.g. national scale) or whether the 
inclusion of site-specific parameters would be useful (e.g. local scale) (Burns et al. 2017). There is a 
limited, but growing knowledge of temporal fluctuations of pharmaceutical concentrations in the 
environment (Burns et al. 2018). Currently, there are no apparent models or initiatives to include 
this temporal variability in exposure predictions, which is a limitation of both prioritization and risk 
assessment initiatives. To compensate for enhanced environmental pharmaceutical loading from 
sources not currently considered, as well as spatial and temporal variability, a series of exposure 
scenarios may be calculated similar to Perazzolo et al. (2010). This includes using different 
combinations of WWTP removal estimations (no removal, lowest estimated and highest estimated 
removal) and environmental dilution such as no dilution, factor of 10 dilution and site-specific 
dilution.  
Prioritizations were also developed to include PECs for major active metabolites (Lienert et al. 
2007; Besse et al. 2008; Guo et al. 2016). Evidence showed that the majority of metabolites are less 
potent than parent compound (Obach 2013), although exceptions do exist (Besse and Garric 2010; 
Celiz et al. 2009). In addition, glucuronide or sulfated metabolites may revert back to parent drug 
during water treatment (Jelic et al. 2011), therefore the fraction of these metabolites excreted needs 
to be added to the active pharmaceutical excretion estimate. For a worst case approach, when the 
excretion or potency of an active metabolite is unknown, a total residue approach (e.g. no 
metabolism), similar to that used for ERA, may be employed to account for potentially risky 
metabolites with limited data which might then be assessed in greater detail at a later stage. In 
addition, the current framework focuses on assessing risks of pharmaceuticals singly, which might be 
underestimating risks posed by pharmaceutical mixtures, as mixture toxicity was reported in lab-
based studies (Vasquez et al. 2014). Initially, it is important to master single compound approaches 
prior to introducing further potential error by working with mixtures toxicity models. As the mixture 
toxicity models develop and exposure models presented herein validated, mixture toxicity may be 
incorporated into the framework.  
A prioritization needs to begin by considering as many pharmaceuticals as possible, enabling 
investigation of the large proportion of compounds currently in the  ‘ƵŶŬŶŽǁŶ ?ƌĞŐŝŽŶpresented in 
Figure 1. It is suggested to begin with the aquatic compartment (Figure 5), subsequently assess the 
sediment compartment as PECsurfacewater is required to calculate PECsediment (Figure 4). Both the A 
(apical ecotoxicity endpoints) and B (MoA-based concerns) methods need to be used for both 
aquatic and sediment compartments. For the terrestrial assessment (Figure 5), the mass of 
pharmaceutical sorbed to sludge in the WWTP (PECsludge) along with PECeffluent to represent irrigation 
with reclaimed wastewater both contribute to the PECsoil estimate (Figure 4). The food chain 
assessments, terrestrial (Figure 5) or aquatic (Figure 6), need to be triggered for all pharmaceuticals 
assessed in the relevant environmental compartment (aquatic or soil). This is due to the lack of 
experimental biomagnification and bioaccumulation factors and therefore understanding of how 
pharmaceuticals may accumulate through the food chain. If risks are identified, further refinements 
to exposure may be made, for example estimating drug metabolism in wildlife or employing more 
complex ecosystem modelling approaches. For human assessment, PECsurfacewater is employed in this 
assessment to reflect the worst case scenario or direct exposure such as wildlife swimming or 
drinking. In addition to PECsurfacewater, human assessment also needs to include all compounds which 
undergo a food chain assessment in the either aquatic or soil compartment (Figure 6). This approach 
may also be utilized by water managers when the mere presence, despite limited risks, of certain 
compounds requires action to reduce (e.g. X-ray contrast media). In these cases, the PECsurfacewater 
might be compared directly to the established safety/exposure value (Figure 6). 
These sequential assessments lead to risk score (PEC/PNEC) lists for each considered 
environmental compartment (Figure 5 and 6) as well as two risk score (RS) lists in cases where an A 
and B scenario are presented, Figure 5. A RS of 1 or greater indicates that PEC is equivalent to or 
higher than PNEC, thus a risk may be present. It is suggested that as part of a conservative approach, 
any compound with a RS greater than 0.1 needs to be ranked as a priority, with the largest RS 
ranking as the highest priority. The parameters needed to apply each of the models presented in 
each of the assessment scenarios is listed in the dotted box with a number (Figures 4 to 6). The 
availability of these parameters and reliability of the models/experimental data that are used to 
derive them is crucial to the success of the prioritization and a frequently cited limitation (Guo et al. 
2016; Bouissou-Schurtz et al. 2014). The current knowledge surrounding these parameters and 
models is detailed in Supplementary Material, Table S2. 
Why a new prioritization framework is needed 
 Results demonstrated that over 75 human pharmaceutical prioritizations have been 
undertaken globally (Figure 2). However the multitude of suggested approaches indicate that 
credibility for any particular approach is low, especially when prioritizations are repeated in the 
same region. Different sets of priority compounds are expected based upon the region and scale of 
assessment (Figure 2), due to differences in populations, prescribing practices and hydrology. 
Therefore deriving some level of standardization, such as this framework, might be important for 
harmonization of research and regulatory goals across the world, as prioritization results obtained 
using the same methodology may be comparable. Moreover, our approach goes beyond the aquatic 
compartment to prioritize risks in sediment, soil and exposure via the food chain to provide a 
compressive assessment of all relevant environmental compartments. These considerations are 
especially important when put in a global context. For example, biosolids containing pharmaceuticals 
were noted as a significant pathway by which drugs enter and accumulate in terrestrial environment 
(Kinney et al. 2006b). In addition, compounds might persist in soils and build up to detectable 
concentrations after repeated applications of reclaimed wastewater (Chefetz et al. 2008; Kinney et 
al. 2006a). The use of both treated and untreated reclaimed wastewater and biosolids in agriculture 
is a widely adopted practice in countries suffering from water shortages such as Mexico, Israel, 
Australia and Southern Europe. (Asano et al. 2007; Pedrero et al. 2010; Dalkmann et al. 2012; Lees et 
al. 2016) Further, crops are grown on agricultural soils and cattle producing meat and milk are 
grazing on grasslands that have been amended with sludge-based biosolids and/or reclaimed 
wastewater, which poses a potential risk of indirect human exposure via these products (Mohapatra 
et al. 2016; Paz et al. 2016; Kinney et al. 2006a), which was previously demonstrated (Mottaleb et al. 
2016; Franklin et al. 2016; Malchi et al. 2014).  
The expansion beyond exposure to aquatic compartments is important, however this needs to 
be paired with intelligent approaches of effect estimation capable of capturing pharmaceutical 
potency across diverse range of pharmaceuticals in use, even when available parameters are limited 
to certain physico-chemical properties (e.g. LogP and pKa) and those derived during drug 
development (e.g. Cmax and ADME parameters). This intelligent effect estimation is achieved 
through a combination of apical and MoA-related endpoints in aquatic, benthic and terrestrial 
species belonging to multiple trophic levels. Further, the prioritization of risks from food chain 
exposures in predators as well as humans was only apparently reported in a single prioritization 
(Guo et al. 2016). Our framework builds upon this and reflects realistic dietary habits consisting of 
multiple prey sources and/or vegetation.  
While many aspects of the framework are similar to previous prioritization approaches, a 
major departure concerns consideration of MoA-based issues. Due to their larger assessment factor, 
acute PNECs based upon experimental data were demonstrated as consistently lower than chronic 
PNECs (except when a chronic MoA of concern is present) and therefore protective (Vestel et al. 
2016). The application of this approach might only continue to replicate prioritization of acute 
endpoints, while the more environmentally relevant chronic concerns may go unaddressed. 
Predicted acute data in previous prioritizations are almost entirely derived from unsuitable models 
(e.g. ECOSAR) and have little relevance to real world exposures (Hulzebos and Posthumus 2003; de 
Haas et al. 2011). Instead, development of new chronic QSARs may be more useful for identifying 
pharmaceuticals without a concerning MoA, while other approaches are required to identify 
pharmaceuticals with MoA concerns. 
The MoA considerations involve predicting internal concentrations and relating them to 
therapeutic effect levels in humans such as using the fish plasma model (FPM) (Huggett et al. 2003). 
Endocrine disruption which might be related to human side effects/unintended uses were recently 
observed in fish at concentrations lower than the therapeutic level (Niemuth and Klaper 2016). In 
addition, the decline of vultures (Gyps bengalensis) in Pakistan was linked to the organism exhibiting 
a known side effect of diclofenac (renal failure) (Oaks et al. 2004). Data suggest the therapeutic 
concentration alone may not be sufficiently protective to encompass the concentrations at which 
side effects occur. Therefore application of a safety factor originally suggested to encompass cross-
species sensitivity might also be appropriate to account for potential side effects or effects 
pertaining to the unintended or unauthorized use of a pharmaceutical (Huggett et al. 2003; Niemuth 
and Klaper 2016).  
Teleost fish possess approximately 80% of drug targets through ortholog conservation, while 
certain invertebrate species conserve 50-60% of drug targets (Vebruggen et al. 2018). Exposure of 
Daphnia magna to pharmaceuticals with highly conserved drug targets resulted in predictable 
molecular effects, while exposure to compounds with non-conserved drug targets did not exert an 
effect, implying that  ‘read-across ? approaches might also be important for invertebrates (Furuhagen 
et al. 2014). Therefore, expanding past fish to also predict internal invertebrate concentrations may 
be useful. While less appropriate than for teleost fish, comparison with therapeutic concentrations 
with a safety factor applied may be a useful starting point for flagging compounds which might pose 
a potential risk to invertebrates. Complex bioinformatic approaches may then be utilized to further 
prioritize identified pharmaceuticals based upon the extent of evolutionary conservation of relevant 
receptors. The FPM still requires further experimental work but is a promising tool (Margiotta-
Casaluci et al. 2014; Patel et al. 2016), while development of an invertebrate internal concentration 
(IIC) model which considers invertebrate specific uptake (e.g. invertebrate BCFs) may serve as an 
important step to ensuring potential risks are not missed. The goal of using FPM and potentially IIC is 
to identify the majority of MoA-based concerns (Figure 5), from where targeted and more complex 
predictive approaches beyond the scope of the prioritization framework might be used to inform 
effects testing.  
In summary, our proposed approach builds upon many of the ideas presented in previous 
prioritization exercises and brings them together in a coherent and comprehensive framework. The 
framework does resemble a risk assessment, which is intentional as the aim of the optimal 
prioritization framework is to underpin the ERA process. The goal of a prioritization undertaken 
using this framework will be to identify which pharmaceuticals are of greatest risk and as it is 
holistic, in which environmental compartments/food chains these risks are most likely to emerge. 
After prioritization, the most at-risk species in the relevant environmental compartment or food 
chain might be identified, for example using bioinformatic approaches where % of evolutionary 
conservation of drug targets within the species of interest may be a precursor to testing effects 
(Verbruggen et al. 2018) or more complex ecosystems models employed to better characterize risks 
predicted exposure in food chains. In this way, effect studies might be directed towards the most 
sensitive species and most pertinent endpoints to examine, resulting in a reduction in number of 
test animals required. If evolutionary conservation of a drug target is identified in a species, the 
evaluation can enter the experimental stage. Targeted chronic effects testing is then undertaken and 
environmental exposure may be demonstrated through monitoring. As the effect endpoints are 
most likely non-standard or molecular, approaches such as the adverse outcome pathway (AOP) 
framework (Ankley et al. 2010) might be employed to help put this mechanistic toxicological data in 
context and fed into the risk assessment process. In this manner, pharmaceutical prioritization might 
serve as the basis to inform further risk assessment, such that confidence in prioritization outcomes 
is important. It is recognized that simplicity is advantageous, but difficulties arise when using 
unsuitable QSARs for one size fits all fate and effects estimation. Extensive use of these QSARs leads 
to similar compounds being identified as priority pharmaceuticals continuously (Figure 3), which is 
not beneficial when attempting to identify knowledge gaps. Our framework tackles these biases by 
promoting more intelligent assessment approaches and clearly identifying where research is needed 
to implement this optimum framework. The following section describes data availability and state of 
models required to implement our framework.  
Data availability and quality 
Each of the experimental parameters required to parameterize the exposure and effect 
models mentioned in Figures 4 to 6 were evaluated for availability in Table 3. For brevity, a high-
level overview of each parameter is presented while specifics such as OECD tests, default values and 
QSARs may be found in the Supplementary Material, Table S2. The intention of Table 3 is to detail 
relative availability of data required for our prioritization and highlight where research is needed 
most to achieve parameterization of the optimum framework. In addition to the optimum 
framework, further development and validation of the tools and models in Table 3 might also be 
useful for incorporating environmental considerations earlier in the pharmaceutical development 
process itself. 
The experimental sources in Table 3 relate to environmental measurements or data from the 
peer-reviewed literature. Tailoring the parameters listed as defaults is recommended for localized 
prioritization or those outside of the region they were developed for (e.g. EU). Wastewater 
generation practices vary globally by 50-400 L/per person·day (Henze and Comeau 2008), while 
environmental dilution of 10 may not be sufficiently protective in some regions or overly 
conservative in others (Gardner et al. 2013; Verlicchi et al. 2014).  
It is immediately clear from the status of parameters in Table 3, that models are lacking that 
adequately predict the behavior of ionizable compounds. A red designation in Table 3 indicates a 
research gap that needs to be filled in order to effectively implement the prioritization. The 
 ‘Intelligent assessment of Pharmaceuticals in the Environment (iPiE) ? column was included in Table 3 
to demonstrate the type of data and estimated coverage held by industry which is currently being 
developed into an online database as part of a large European initiative. It is anticipated that this 
database will become available to the research community in the future. The database may be used 
as a data ƐŽƵƌĐĞŽƌƚŽƌĞĚƵĐĞƚŚĞ ‘DĂƚƚŚĞǁĨĨĞĐƚ ?ǁŚĞƌĞƉƌĞǀŝŽƵƐůǇƐƚƵĚŝĞĚĐŽŵƉŽƵŶĚƐĂƌĞƐƵďũĞĐƚ
to similar tests repeatedly. The iPiE database contains high quality data and thus might reduce 
reliance on unsuitable experimental data or QSARs. Prioritization is an exercise in efficiency, and a 
database such as this might vastly improve the efficiency of the process. 
Conclusions 
 The overall reliability of the models required to progress through the proposed prioritization 
framework (Figures 4 to 6) was evaluated based upon the status of parameters from the previous 
section and experimental validation from the literature. Detailed results may be found in 
Supplementary Material, Table S2, while a summary of results is presented in Table 4. The largest 
knowledge gaps and therefore greatest research needs are easily identifiable by the red colors and 
pertain largely to terrestrial species and invertebrates both aquatic and terrestrial. This summary 
may be used as a guide to direct further development of predictive models that are a) suitable and 
validated for pharmaceuticals and b) have applicability domains encompassing the majority of 
compounds. As these knowledge gaps are filled, the optimal prioritization framework might emerge 
and be suitable for assessing risks to relevant environmental compartments globally so that a 
greater focus may be placed  upon risk mitigation where is it most needed.  
The majority of pharmaceuticals do not have an ERA and current risk assessment approaches 
do not address all relevant environmental compartments and exposure scenarios. There is therefore 
a real need for a prioritization methodology to identify those molecules that have not been tested 
which are of a potential concern in the environment as well as potentially identifying where risk 
mitigation measures may be required. Many prioritization approaches were proposed in the 
literature. The majority of these use a risk-based approach, which in many cases is the combination 
of limited or inappropriate hazard- and effect-based methods not suited for all pharmaceuticals or 
exposure scenarios. The methods have tended to focus on aquatic exposure scenario and on the few 
regions of the world with a developed wastewater and drinking water treatment infrastructure and 
low levels of grey water reuse. This review has brought together the most promising components 
from several approaches and presented them as part of a holistic framework for prioritizing risks 
posed by pharmaceuticals to multiple environmental compartments. Much research is still required 
to confidently administer the prioritization framework, including both model development and 
validation; nevertheless it could form an important part of the risk assessment process to ensure 
risks to environment are not missed.  
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Figure 1. A qualitative representation of the estimated active pharmaceutical ingredients (APIs) 
registered for market use in the UK (eMC, 2017) (grey, n=1912), proportion of pharmaceuticals 
identified thus far by prioritisation exercises (blue, n=332), roughly the portion of total UK registered 
APIs that have EMA ERA data (green) and the overlap between APIs prioritised thus far and also 
assessed within the EMA ERA framework (blue and green). 
  
 Figure 2. Areas of the world where priority pharmaceuticals have been identified by either risk-, 
hazard- or exposure-based approaches. Colouring corresponds to the number of prioritisations 
undertaken within that region (i.e. 1 to 8). The top 5 priorities selected for each region are based on 
the number of times a pharmaceutical appears on applicable priority lists. The font colour indicates 
the type of prioritisation that identified these compound: black: entirely or vast majority risk-based, 
red: entirely hazard based, green: entirely exposure based, blue: at least 50% risk-based while 
remainder are exposure-based and orange: at least 50% risk-based while remainder are hazard-
based.  
  
Table 1. Pharmaceuticals classified 3 or more times (n=76) sorted initially by prioritisation approach 
that identified each of the 76 compounds, then by therapeutic class within each approach. 
  
Category Therapeutic Class  Pharmaceutical 
R
is
k 
Antibiotics (16) 
Amoxicillin, Ampicillin, Azithromycin,  Cephalexin, 
Ciprofloxacin, Clarithromycin, Clindamycin, Clotrimazole, 
Erythromycin, Levofloxacin, Lincomycin, Metronidazole, 
Ofloxacin, Oxytetracyline, Sulfamethoxazole, 
Trimethoprim 
Hormones    (including 
synthetic) (10) 
 
Equilenin, Estradiol, Estriol, Estrone, Ethinylestradiol, 
Levonorgestrel, Medoxyprogesterone, Mestranol, 
Noreistherone, Testosterone 
Analgesic (8) 
Acetylsalicylic acid, Dextropropoxyphene, Diclofenac, 
Ibuprofen, Mefenamic acid, Naproxen, Paracetamol, 
Tramadol, Ketoprofen 
Antidepressant (6) Amitriptyline, Citalopram, Fluoxetine, Norfluoxetine, 
Paroxetine, Sertraline 
Lipid-lowering agent (5) Atorvastatin, Bezafibrate, Clofibrate, Gemfibrozil, 
Simvastatin 
Cardiovascular agent (4) Felodipine, Fenofibrate, Losartan, Valsartan 
Anti-cancer (4) Cyclophosphosphamide, Ifosfamine, Tamoxifen 
Beta-blocker (3) Atenolol, Metoprolol, Propranolol 
Antidiabetic (2) Metformin, Glyburide 
Contrast agent (2) Iopamidol, Iopromide 
Diuretic (2) Furosemide, Hydrochlorothiazide 
Anaesthetic (1) Lidocaine 
Antiarrhythmic (1) Amiodarone 
Antibacterial (1) Triclosan 
Antifungal (1) Ketoconazole 
Antihistamine (1) Loratadine 
Anti-convulsant (1) Carbamazepine 
Antineoplastic (1) Mitotane 
Antiretroviral (1) Ritonavir 
Benzodiazepine (1) Oxazepam 
H2 Blocker (1) Ranitidine 
Proton pump inhibitor (1) Omeprazole 
 Antibiotic (10) 
Amoxicillin, Azithromycin, Ciprofloxacin, Clarithromycin, 
Erythromycin, Levofloxacin, Lincomycin, Ofloxacin, 
Sulfamethoxazole, Trimethoprim 
Ex
po
su
re
 
Analgesic (5) Diclofenac, Ibuprofen, Naproxen, Paracetamol, 
Ketoprofen 
Lipid-lowering agent (4) Atorvastatin, Bezafibrate, Gemfibrozil, Simvastatin 
Anti-cancer (3) Cyclophosphosphamide, Ifosfamine, Tamoxifen 
Cardiovascular agent (3) Irbesartan, Losartan, Valsartan 
Diuretic (2) Furosemide, Hydrochlorothiazide  
Antidiabetic (2) Metformin, Glyburide  
Antidepressant (1) Paroxetine  
Beta-blocker (1) Atenolol  
Anti-convulsant (1) Carbamazepine  
H2 Blocker (1) Ranitidine  
H
az
a
rd
 
Hormones (including 
synthetic) (9) 
Equilenin, Estradiol, Estriol, Estrone, Ethinylestradiol, 
Etonogestrel, Levonorgestrel, Medoxyprogesterone, 
Testosterone 
Antidepressant (6) Amitriptyline, Citalopram Fluoxetine, Norfluoxetine, 
Paroxetine, Sertraline 
Lipid-lowering agent (5) Atorvastatin, Bezafibrate, Clofibrate, Gemfibrozil, 
Simvastatin 
Antibiotic (5) Amoxicillin, Ciprofloxacin, Clotrimazole, Erythromycin, 
Sulfamethoxazole 
Cardiovascular agent (3) Felodipine, Fenofibrate, Irbesartan 
Analgesic (2) Diclofenac, Ibuprofen 
Antihistamine (2) Clemastine, Loratadine 
Contrast agent (2) Iopamidol, Iopromide 
Anticancer (1) Tamoxifen 
Antineoplastic (1) Mitotane 
Beta-blocker (1) Propranolol 
 
 F
ig
u
re
 3
. P
h
arm
aceu
ticals id
en
tified
 as p
rio
rities th
ree o
r m
o
re tim
es (n
=7
6
) fro
m
 o
n
 th
e 76
 ap
p
ro
ach
es review
ed
 in
 th
e literatu
re.  
  
0 5 10 15 20 25 30
Diclofenac
Ethinylestradiol
Ciprofloxacin
Paracetamol
Ibuprofen
Carbamazepine
Clarithromycin
Estradiol
Erythromycin
Amoxicillin
Sulfamethoxazole
Propranolol
Fluoxetine
Trimethoprim
Bezafibrate
Sertraline
Gemfibrozil
Azithromycin
Simvastatin
Atenolol
Mefenamic acid
Amitriptyline
Naproxen
Ofloxacin
Estrone
Furosemide
Acetasalicylic acid
Atorvastatin
Norethisterone
Metformin
Tamoxifen
Clotrimazole
Metronidazole
Hydrochlorothiazide
Estriol
Oxytetracyline
Tramadol
Triclosan
Fenofibrate
Irbesartan
Valsartan
Lincomycin
Metoprolol
Dextropropoxyphene
Felodipine
Ketoconazole
Loratadine
Amiodarone
Mitotane
Ketoprofen
Ranitidine
Omeprazole
Paroxetine
Cephalexin
Oxazepam
Clemastine
Etonogestrel
Medoxyprogesterone
&\FORSKRVSKRVSKDP«
Ifosfamine
Lidocaine
Ampicillin
Citalopram
Losartan
Mestranol
Testosterone
Equilenin
Norfluoxetine
Clindamycin
Clofibrate
Iopamidol
Iopromide
Levofloxacin
Ritonavir
Levonorgestrel
Glyburide
No. of times selected as priority pharmaceutical
H
aza
rd
E
xpo
su
re
R
isk Q
u
otie
nt
Table 2. Strengths and limitations of major parameters in current risk-based prioritisation approaches and the opportunities and threats for developing a new or improved 
approach. 
 Parameter Strengths Limitations Opportunities Threats 
Ex
po
su
re
 
Simple PEC  
x Cost effective 
x Tailored to be local or regional 
x Applied to all APIs for which 
consumption data available 
x Simple algorithms and EMA defaults 
available. 
x Provide basis for local/regional 
monitoring campaigns 
x No over-the-counter usage 
x No hospital usage  
x Prescription data only available for 
select regions 
x Single environmental pathway (WWTP) 
x Not representative of local wastewater 
usage/environmental dilution. 
x Variability in patient metabolism 
x Alternative methods to derive usage 
x Incorporate other major sources (e.g. 
manufacturing effluent) 
x Approach that can assess the 87% of 
APIs in use that without ERA data 
x Development/validation of exposure 
models for understudied compartments 
such as soil, sediment and porewater. 
 
x First tier may 
unknowingly eliminate 
compounds (e.g. 
assessment trigger 
values) 
x Unsuitable exposure 
models (e.g. ionisable) 
Higher tier 
spatial PEC 
x Multiple pharmaceutical sources 
x Incorporate mixing with 
pharmaceuticals transported from 
upstream 
x Identify local concentration hot spots 
x Incorporate hydrological 
characteristics/long term flow trends 
x Only developed for specific 
regions/watersheds 
x Access limited 
x Similar pharmaceutical consumption, 
WWTP removal and metabolisms 
issues to simple PEC 
x Development of open-access platforms to 
make predictions 
x Open-access tools to develop spatial 
models for currently unstudied areas 
x Incorporate sludge and soil sorption 
models which can account for ionisable 
compounds 
x Expand past surface water to include 
sediment and vulnerable soils (e.g. 
agriculture) 
x Probabilistic risk assessment 
 
MEC 
x Confidence in results 
x All environmental pathways considered 
(when representative sampling used) 
x Localised  
x Limited number of APIs/compounds 
x Costly 
x Maximal MECs 
x Limits of detection 
x Unrepresentative sampling 
x Limited to pharmaceuticals already 
detected/already of concern 
x Lower cost monitoring approaches 
x Improved limits of detection 
x Use to confirm risky predictions 
x  Poorly representative 
sampling 
 
 
 
Table 2 (continued). Strengths and limitations of major parameters in current risk-based prioritisation approaches and the opportunities and threats for developing a new 
or improved approach. 
P NExperimental x Regulatory relevance x Limited availability x Create comprehensive database of LQGXVWU\KHOGGDWDWRSUHYHQWµ0DWWKHZ
x Missing specific MoA 
concerns 
(chronic/acute) x Confidence in results 
 
x Limited relevance of acute data 
x Chronic ECOSAR not yet validated for 
APIs and likely not robust 
x Considers only apical endpoints 
(mortality, reproduction, growth) 
EIIHFW¶ x Experimentally filling 
data gaps defeats 
purpose of desk-based 
prioritation. 
ECOSAR x Rapid, can be applied to all APIs. 
x Heavy reliance on predicted data, 
µ0DWWKHZ(IIHFW¶ 
x Large arbitrary safety factors  
x Improve chronic QSAR 
x µ0DWWKHZHIIHFW¶ 
x Missing specific MoA 
concerns 
FPM 
x Readily available pharmacokinetic 
parameters 
x QSAR to predict BCF based on 
octanol-water partition coefficient (Kow) 
x Can be applied to vast majority of APIs 
x Covers mode of action (MoA) concerns 
x BCFs not experimentally available for 
most APIs 
x Applicability of BCF QSAR 
x Only relevant for fish 
x Experimental validation limited, but 
growing 
x Expand to invertebrates (water column, 
benthos and soil) 
x Reduce animal testing by prioritising 
legacy APIs and focusing efforts towards 
those most likely to have an adverse 
impact 
x Use internal concentrations to develop 
predator exposure models 
x Unsuitable uptake 
models (e.g. ionisables) 
x Miss specific MoA 
concerns pertaining to an 
$3,¶VVLGHHIIHFWRIIODEHO
use 
ADI 
x Can calculate for all APIs which have 
mammalian toxicity studies 
x Based on arbitrary uncertainty factors 
to ensure conservative risk 
assessment 
x Focuses on water exposure (surface 
and drinking) 
x Include a diet component (fish, meat, 
water, crops) 
x Diet (fish, meat, water, 
crops) 
 
 Figure 4. Breakdown of the relationship between exposure scenarios and the generalised parameters required to calculate the emissions. Numbers refer to Supplementary 
Tables S1 and S2 where greater of the derivation and limitations of each parameter is given.  
 
Figure 5. High level schematics demonstrating the prioritisation of risk posed to three trophic levels in aquatic, sediment and soil systems. Secondary approaches to 
prioritising risks to aquatic/sediment systems based on pharmaceutical uptake and internal concentrations compared to human therapeutic concentrations are also shown 
(B). Predatory wildlife food chain risk prioritisation which considers exposure to multiple prey/environmental sources (terrestrial). Numbers refer to Supplementary Tables 
S1 and S2 where greater of the derivation and limitations of each parameter is given. 
 
  
Figure 6. Prioritisation of pharmaceutical risks to humans considering both water intake or direct water exposure as well as other dietary sources such as plants and 
meat. Predatory wildlife food chain risk prioritisation which considers exposure to multiple prey/environmental sources (aquatic). Numbers refer to Supplementary Tables S1 and 
S2 where greater of the derivation and limitations of each parameter is given. 
Table 3. Generalised overview of the availability of parameters required to estimate environmental pharmaceutical 
exposure and effects in multiple compartments based on the models contained within the prioritisation framework. 
Default refers to suggestions from the EMA (2006) guidelines. Models or methods to derive the parameter are listed in 
Table S2. 
Model Parameter iPiE Experimental 
source 
Model Default (Table S2) 
Human use 1) (1) API consumption   
 
mg/yr Table S2 Table S2 Table S2  
PECexcreta (2) Human metabolism 
  
Fexcreta     
PECinfluent (3) Wastewater dilution 
 
L/person·day     
PECeffluent (4) WWTP Removal  
 
% Biodegration 
% Sorption     
PECsurface water (5) Environmental 
dilution       
PECsediment (6) Equilibrium 
partitioning  Sediment (Kd)     
(7) Degradation  DT50 (sediment)     
PECsoil (6) Equilibrium 
partitioning  Soil (Kd)     
(7) Degradation  DT50 (soil)     
(8) Application rate  kg/ha·year 
    
Toxicity (9) Algae/daphnia/fish Acute EC50     
(10) Algae/daphnia/fish Chronic EC50     
PNEC (11) Assessment factor      
Internal PEC (12) Fish  FPC     
(13) Invertebrate   IPC 
 
   
Internal PNEC (14) Therapeutic plasma 
concentration  HtPC  
   
Toxicity (9) Benthic invertebrate
 
 EC50     
CEarthworm (15) BCF      
Toxicity (9) Earthworm
  
LC50     
CPlant (15) BCFplant      
Toxicity  (16) Mammal   NOAEL     
Toxicity  (17) Bird  NOEC     
PECDiet(wildlife) (18) Uncertainty factor      
(19) Feeding behaviour  
 
   
Acceptable 
daily intake  
(20) Uncertainty factor  ADI 
 
   
PECDiet(human) (21) Diet      
XXXXX Full dataset for pharmaceuticals released to market post 2006. 
XXXXX Available or applicable to majority pharmaceuticals. In iPiE column, relative to dataset (n=300). 
XXXXX Available but not applicable to ionizables or other applicability domain exist. 
XXXXX Available or applicable to few pharmaceuticals. 
XXXXX Model to predict parameter does not exist. 
Table 4. Summary of the current reliability of models included in the optimum prioritisation framework based on the 
suitability of relevant parameter estimation and reported validation in the literature. 
Endpoint 
Exposure  Effects 
Model Model 
reliability  Model 
Model 
reliability 
Aquatic plant PECsurfacewater   
Acute 
 
 
Chronic 
 
Aquatic invertebrate PECsurfacewater 
 
 
Acute 
 
 
Chronic 
 
Aquatic invertebrate Invertebrate plasma concentration (IPC)
 
 
 
Read across 
 
Aquatic wildlife (fish) PECsw 
 
 
Acute 
 
 
Chronic 
 
Aquatic wildlife (fish) Fish plasma concentration (FPC)
 
 
 Read across 
 
 
Terrestrial plant PECsoil 
 
 
Acute 
 
 
Chronic 
 
Terrestrial invertebrate PECsoil 
 
 
Acute 
 
 
Chronic 
 
Terrestrial invertebrate PECsediment 
 
 
Acute 
 
 
Chronic 
 
Terrestrial invertebrate Invertebrate plasma concentration (IPC)
 
 
 
Read across 
 
Terrestrial wildlife (birds) PECdiet   Acute  
 
Chronic 
 
Terrestrial wildlife (birds) PECbird   Chronic  
Human PECdiet 
 
 
ADI 
 
Human PECsurfacewater 
 
 
ADI 
XXXXX Model exists and is validated for pharmaceuticals.  
XXXXX Model exists and used for pharmaceuticals, but lacks validation. 
XXXXX Model exists, but not designed for pharmaceuticals.  
XXXXX No model has been developed yet. 
 
  
Application of prioritization approaches to optimize environmental monitoring 
and testing of pharmaceuticals 
Emily E. Burns, ? Laura J. Cater, ? Jason  Snape,§ Jane Thomas-Oates, ? Alistair B.A. Boxall* ? 
 ?Chemistry Department, University of York, Heslington, YO10 5DD, United Kingdom 
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Availability of European Medicines Agency ERA data through a European Public Assessment Report (EPAR) 
 
Table S3. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. Usage data 
was collected from the National Health Service Prescription Cost Analysis 2012 (NHS, 2012). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Acamprosate 
Calcium 4633.995 N Amiodarone HCl 3129.719 N Baclofen 848.1401 N 
Acrivastine 40.1273 N Amisulpride 2504.559 N Balsalazide Sodium 8578.065 N 
Acyclovir 15503.25 N Amitriptyline HCl 10431.37 N Bendroflumethiazide 1504.737 N 
Adapalene 5.75915 N Amlodipine 5623.418 Y benzerazide 1711.785 N 
Alendronic Acid 2485.896 Y Amoxicillin 123080.7 N Benzoyl Peroxide 2.777593 N 
Alfuzosin HCl 198.6387 N Anastrozole 19.01404 N Benzydamine HCl 8.119974 N 
Alimemazine Tartrate 42.47056 N Aripiprazole 168.2959 Y Betahistine HCl 1640.354 N 
Allopurinol 35355.61 N Acetylsalicylic acid 76766.37 Y Betamethasone Valerate 0.103622 N 
Alverine Citrate 2008.694 N Atenolol 19849.26 N Bezafibrate 1.102586 N 
Amantadine HCl 577.1469 N Atorvastatin 18301.26 N Bicalutamide 7808.065 N 
Amiloride 202.2389 N Azathioprine 2824.994 N Bisacodyl 662.9771 N 
Aminophylline 
Hydrate 5359.066   Azithromycin 15020.11 N Bisoprolol Fumarate 126.8647 N 
Brinzolamide 1987.094 N Cetomacrogol 65.58092 N Centrimide 0.492776 N 
Bumetanide 63.38782 N Chloramphenicol 4.057731 N Cetirizine HCl 1726.327 N 
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Table S4. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 
2012. Usage data was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Budesonide 73.6161 Y Chlohexidine Gluconate 0.047155 N Clonazepam 24.876 N 
Digoxin 12.81834 N Erythromycin 17586.66 N Flecainide Acetate 2029.77 N 
Buprenorphine 65.85415 Y Chlorphenamine Maleate 215.1903 N Clonidine HCl 1086.108 N 
Bupropion HCl 51.79441 Y Chlorpromazine HCl 843.0926 N Clopidogrel 13584.8 Y 
Buspirone HCl 3.122872 N Chlortalidone 297.7189 N Clotrimazole 204.5456 N 
Calcipotriol 3.116136 N Ciclosporin 641.8038 Y Codeine 47949.39 N 
Calcium Acetate 1711.371 N Cimetidine 2734.228 N Colchicine 7.831715 N 
Candesartan Cilexetil 2282.735 N Cinnarizine 496.6023 N Crotamiton 1.484619 N 
Captopril 365.6421 N Ciprofloxacin 6233.46 N Cyclizine HCl 1750.654 N 
Carbamazepine 37897.98 N Citalopram Hydrobromide 8734.843 N Cyprote Acetate 38.63865 N 
Carbidopa 2875.356 Y Clarithromycin 14320.11 N Dabigatran Etexilate 1222.095 Y 
Carbimazole 204.5619 N Clavulanate  818.0046 N Dantrolene  140.8969 N 
Carbocisteine 62872.02 N Clindamycin  - N Desmopressin Acetate 1.849407 N 
Carvedilol 327.1891 N Clobazam 107.8139 N Desogestrel 16.96663 N 
Cefalexin 9965.047 N Clobetasol Propionate 2.279332 N Desoloratidine 58.47969 N 
Celecoxib 2534.791 Y Clomipramine HCl 730.8683 N Dexamethasone 17.56267 Y 
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Table S5. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. 
Usage data was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Dexamfetamine Sulfate 24.88827 N Doxazosin Mesilate 1027.151 N Famotidine - N 
Dexketoprofen 4.034275 N Doxycycline Hyclate 3430.624 N Felodipine 815.3964 N 
Dextromethorphan 
Hydrobromide OTC Y Duloxetine HCl 1991.763 Y Fenofibrate 3771.716 Y 
Dextroprop HCl 571.3053 N Dutasteride 8.334655 N Fentanyl - Y 
Diazepam 619.8726 N Enalapril Maleate 1346.481 N Fesoterodine Fumarate 39.92008 Y 
Diclofenac Sodium 8240.328 N Entacapone 4430.08 Y Fexofenadine HCl 9935.872 N 
Dicycloverine HCl 184.5628 N Eplerenone 230.6903 N Finasteride 376.9499 N 
Gabapentin 124353.5 N Ibuprofen 99212.55 Y Lercanidipine HCl 846.4954 N 
Dihydrocodeine Tartrate 9609.232 N Escitalopram 368.8627 N Flucloxacillin Sodium 53702.76 N 
Diltiazem HCl 21015.41 N Estriol 5.740766 N Fluconazole - N 
Dimeticone  21.90098 N Ethinylestradiol  14.66202 N Fludrocortisone 
acetate 1.274797 N 
Dipyridamole 2527.264 N Ethosuximide 779.641 N Fluorouracil  1.001543 N 
Docusate Sodium 9354.674 N Etodolac 3335.156 N Fluoxetine HCl 5236.459 N 
Domperidone 1320.033 N Etoricoxib 892.8282 N Flupentixol HCl 8.633705 N 
Donepezil HCl 305.721 Y Etynodiol Diacetate 2.65181 N Fluticasone Propionate 5.465809 Y 
Dorzolamide  0.183812 N Exemestane 99.7522 N Folic Acid 644.0475 N 
Dosulepin HCl 3032.475 N Ezetimibe 685.6289 N Frusemide 155.3189 N 
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Table S6. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. Usage data 
was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Mebendazole 112.712 N Metoclopramide HCl 637.5506 N Neomycin Sulfate 62.92856 N 
Gemfibrozil - N Imipramine HCl 299.5535 N Letrozole 38.31931 N 
Gilbenclamide 27.25068 N Indapamide 220.0683 N Levetiracetam 44519.27 Y 
Gliclazide 36347.48 N Indometacin 640.33 N Levocetirizine 27.01289 N 
Glimepiride 74.04899 Y Indoramin 119.0657 N Levodopa 19906.56 Y 
Glipizide 57.49691 N Ipratropium Bromide 3.282406 N Levofloxacin - Y 
Glyceryl Trinitrate 50.02094 N Irbesartan 16480.61 Y Levonorgestrel 0.437523 N 
Haloperidol 24.58707 N Isosorbide Mononitrate 6874.212 N 
Levothyroxine 
Sodium 65.59779 N 
Hydralazine HCl  257.4103 N Itraconazole 475.082 N Lidocaine HCl 0.565125 Y 
Hydrochlorothiazide - Y Ivabradine 71.02108 Y Lisdexamfetamine Dimesylate - N 
Hydrocortisone -- Y Ketoconazole 23.99151 Y Lisinopril 4759.135 N 
Hydroxycarbamide 2954.171 Y Ketoprofen 235.9665 N Lofepramine HCl 1129.279 N 
Hydroxychloroquine Sulfate 533.517 N Labetalol HCl 1644.713 N Loperamide HCl 236.7046 N 
Hydroxyzine HCl 536.2263 N Lacidipine 62.06591 N Loratadine 819.2082 N 
Hyoscine Butylbromide 865.77 N Lamotrigine 8726.156 N Lorazepam 36.56924 N 
Hypromellose 0.387105 N Lansoprazole 16175.15 N Losartan Potassium 16690.98 N 
Ibandronate Sodium - N Lantanoprost 0.531841 N Lymecycline 20293.65 N 
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Table S7. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. Usage data 
was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Oxazepam 76.3154 N Pramipexole 103.1683 Y Quinine Bisulfate 6206.635 N 
Mebeverine HCl 23210.73 N Metoprolol Tartrate 2294.196 N Nicorandil 1646.397 N 
Medroxyprogesterone 
acetate 10027.43 N Metronidazole 11153.06 N Nicotine 384.8292 N 
Mefenamic Acid 55.98768 N Miconazole Nitrate 185.0328 N Nifedipine 2999.857 N 
Melatonin 289.0645 Y Mirtazapine 3693.804 N Nitrazepam 118.9559 N 
Meloxicam 172.5621 N Mometasone Furoate 0.155947 N Nitrofurantoin 3179.265 N 
Memantine HCl 10027.43 Y Montelukast 502.6383 N Norethisterone 189.848 N 
Meptazinol HCl 1194.181 N Morphine Sulfate 4215.292 N Nortriptyline 482.7553 N 
Mesalazine  77618.76 N Moxifloxacin HCl  N Nystatin - N 
Metformin 937082.8 Y Moxonidine 5.73321 N Oestrogens Conjugated 34.36688 Y 
Methadone 1557.91 N Mycophenolate Mofetil 8471.95 Y Olanzapine 423.4855 Y 
Methocarbamol 9850.463 N Nabumetone 1900.28 N Olmesartan Medoxomil 480.2685 N 
Methotrexate 159.9306 Y Naftidrofuryl Oxalate 1315.567 N Olopatadine HCl  Y 
Methycellulose 2211.906 N Naloxone HCl  N Omeprazole 20213.56 N 
Methyldopa 2485.886 N Naproxen 144631.8 N Ondansetron HCl  N 
Methylphenidate HCl 770.8237 N Nebivolol 82.73712 N Orlistat 6022.41 Y 
Methylpredisolone - N Nefopam HCl 863.1576 N Oseltamivir Phosphate - Y 
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Table S8. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. Usage data 
was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Simeticone 649.7117 N Tamsulosin HCl 198.2635 N Tranexamic Acid 13377.8 N 
Oxybutynin 357.7791 Y Pravastatin Sodium 2858.58 Y Quinine Sulfate 23334.29 N 
Oxycodone HCl 1252.609 N Prazosin HCl 5.749455 N Raberprazole 
sodium 254.6749 N 
Oxytetracycline 17705.12 N Prednisolone 1447.857 N Raloxifene - Y 
Pantoprazole 1031.968 Y Pregabalin 21033.26 Y Ramipril 5454.358 N 
Paracetamol  2222361 N Primidone 1738.296 N Ranitidine HCl 34853.71 N 
Paroxetine HCl 1168.383 N Prochlorperazine Maleate 398.1138 N 
Rasagiline 
Mesilate 4.18359 Y 
Perindopril Arginine 26.24768 N Procyclidine HCl 163.6549 N Repaglinide 10.79511 Y 
Perindopril Erbumine 927.4732 N Promazine HCl 183.0343 N Risedronate Sodium - N 
Permethrin 0.645626 N Promethazine HCl 372.5662 N Risperidone 82.93323 N 
Phenobarbital 566.2101 N Propranolol HCl 9604.497 Y Ropinirole HCL 73.94691 N 
Phenoxymethylpenicillin  30213.85 N Propylthiouracil 193.4775 N Rosuvastatin Calcium 785.6995 N 
Phenytoin 12046.42 N Pseudoephedrine HCl 329.8656 Y Salbutamol 78.13675 N 
Pholcodine 103.1683 N Pyridostigmine bromide 717.8097 N Saxagliptin 40.0278 Y 
Pioglitazone HCl 1285.504 Y Pyridoxine HCl 242.4529 N Sertraline HCl 14646.35 N 
Piroxicam 24.32061 N Quetiapine 9937.301 N Sevelamer 7370.68 Y 
Pizotifen Malate 24.88417 N Quinapril HCl  N Sildenafil Citrate - Y 
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Table S9. Assessment of the availability of EPARs (see main text) for the top 350 prescribed pharmaceuticals by mass in England from the year 2012. Usage data 
was collected from the National Health Service Prescription Cost Analysis 2012 (see main text). 
Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available Pharmaceutical 
Mass 
prescribed 
(2012) 
EPAR 
available 
Simvastatin 43228.17 Y Telmisartan 942.8226 Y Trazodone HCl 3261.608 N 
Sitagliptin 6084.335 Y Temazepam 660.796 N Triamcinolone Acetonide - N 
Sodium Cromoglicate 165.2364 N Terazosin Hydrochloride - N Triamterene - Y 
Sodium Feredate 2654.143 N Terbinafine HCl 6419.333 N Trifluoperazine 14.17442 N 
Sodium Fluoride 3.177142 N Testosterone 158.8291 Y Trihexyphenidyl HCl 19.41714 N 
Sodium Picosulfate 301.9395 N Tetracycline 945.4462 N Trimethoprim 9618.376 N 
Solifenacin 452.7087 N Theophylline 7152.281 N Trosoium chloride 350.868 N 
Sotalol HCl 2722.237 N Thiamine HCl 8037.643 N Ursodeoxycholic Acid 5716.05 N 
Spironolactone 2345.547 N Tibolone 31.1085 N Valaciclovir 467.6434 N 
Sulfamethoxazole - N Ticagrelor 777.7494 Y Valproic Acid 10533.69 N 
Sulfasalazine 53559.59 N Tiotropium 2.634269 N Valsartan 6512.622 Y 
Sulpiride 1961.786 N Tizanidine HCl 29.67087 N Verapamil HCl 5771.087 N 
Sumatriptam Succinate 749.3011 N Tolbutamide 2603.915 N Varenicline Tartrate 18.53741 Y 
Tacrolimus 23.43627 Y Tolterodine 118.3774 N Venlafaxine 11206.86 N 
Tadalafil 92.56042 Y Topiramate 2315.892 Y Warfarin Sodium 1192.922 N 
Tamoxifen Citrate 456.7937 N Tramadol 43206.84 N Zolpidem Tartrate 141.9548 N 
Zonisamide 509.5191 Y Zopiclone 721.6331 N Zuclopenthixol hydrochloride 74.3017 N 
National Health Service, 2012. Prescription Cost Analysis - England 2012. https://digital.nhs.uk/catalogue/PUB10610 (accessed January 3, 2018 ). 
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Evaluation of Parameters required for prioritisation framework 
 
Table S10.  Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised in Table 3 of 
the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
Number Variable Experimental 
source 
Model/ 
predictive 
tool/ default 
Applicability 
domain Experimental validation Method limitations/ Suggestions 
(1) 
API usage in 
specific region  
Consumption 
(mg/yr) 
Prescription analysis N/A N/A 
1. Found good agreement 
between PECs/MECs in WwTP 
effluent (11 APIs) [1]. 
x No over-the-counter API usage. 
 
x Hospital usage should be included if possible [2]. 
 
 
x Method can be paired with the Fpen approach to 
cover all APIs. 
x Route of administration can affect metabolism, the 
highest fraction excreted unchanged found in the 
literature should be used for a worst case approach. 
x Ensure combination drugs are split into constituent 
parts. 
x Run the prioritisation with no metabolism to identify 
whether the metabolites of  particular highly 
metabolised parent pharmaceuticals require 
research, as metabolites are rarely more potent than 
the parent pharmaceutical. 
Sales data N/A N/A 
PECs derived from sales data 
are greater than local maximum 
MECs in study of 56 APIs [3]. 
x Not publicly available. 
 
Market penetration 
(Fpen) estimate 
Fpen 1% (default)  
[4]  x All APIs. 
1.) Derived  1% Fpen default 
based on 95th percentile of 800 
APIs [4]. 
2.) Evaluated 10 MECs with 
PECs derived using default 
Fpen, PECs were conservative 
[5]. 
x Generalised, consumption over/under estimations 
likely. 
x Limited to a specific product, not additive across 
pharmaceuticals in multiple formulations or prodrugs. 
(2) 
API emission 
to sewage 
 
% excreted 
unchanged 
(Fexcreta) 
In vivo metabolism 
studies in man N/A 
x All administered 
internally (including 
metabolites). 
Variation in reported Fexcreta 
identified as source of PEC error 
(0-200% change in PEC) [6]. 
x Topical and ophthalmic preparations generally no 
metabolism, assume 100% excretion [7].  
 
x Sulfato-and glucuronide metabolites (cleaving) 
possible in WwTP, could increase wastewater parent 
API loads, include this fraction in PEC [8]. 
 
x Suggested that largest reported Fexcreta value in 
literature generates the most relevant PECs [9]. 
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Table S11. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
Number Variable Experimental 
source 
Model/ 
predictive tool/  Applicability domain Experimental validation Method limitations/ Suggestions 
(3) 
Wastewater 
dilution 
Wastewater 
(L/person·day) 
Wastewater entering 
WWTP averaged per 
capita 
Default: 200 L/day 
[10,11] Europe 
1.)Validated 200 L/day per 
capita wastewater generation for 
Germany [12]. 
 
2.) Wastewater dilution will vary 
based on water usage practices 
throughout world, 50-400 L/day 
[13]. 
Consider regional water usage patterns to not 
overestimate environmental dilution. 
(4) 
WWTP 
removal 
 
% removal 
efficiency 
(%RE), split into 
% sorption to 
sludge and % 
biodegredation 
Estimated removals 
based on difference 
between influent and 
effluent concentrations 
SimpleTreat 4.0 
[14] 
x Monovalent organic 
acids, bases, 
neutrals 
x pH 3-7, -1 < 
logKow >3). 
 
x Koc may be 
underestimated for 
organic acids, more 
so for bases. 
 
x Not suitable for 
ionic surfactants. 
1.) Neutral organics, predicted 
within +/- 5% removal [15]. 
 
2.) 10 compounds to challenge 
applicability domain, found KOC 
regressions good for acids, but 
not for bases (KOC better to be 
experimentally determined [16]. 
 
x Improvements in mechanistic understanding and 
modelling of sorption for ionsables still needed [17].   
 
x Experimental values vary substantially, if used, use 
lowest % RE reported in literature.  
 
x Organic bases preform more poorly than acids 
because when ionised, cations could have 
electrostatic interactions with negatively charged 
particles (ie. sediment, colloids, sludge), so use 
experimental Koc  when possible. 
 
x SimpleTreat 3.1 (and newer) suggested for first tier 
risk assessment (considers ionic state of API) [4]. 
(5) 
Environmental 
Dilution 
Dilution factor 
Monitor river flow and 
WWTP discharge rate 
 
Default:10 [4] Rivers (up to dilution factor of 1000). 
1.) Site specific dilution is 
prefered to calculate PEC.[18] 
 
2.)Dilution factor can lead to an 
uncertainty of up to 695% in 
calculation of PECs.[6] 
x In general, a 10 default dilution factor will provide the 
worst-case assumption (Europe). 
 
x Caution should be taken using this value to estimate 
the dilution factor of small rivers with seasonal 
fluctuations. 
(6) 
Equilibrium 
partitioning 
Soil-water 
partition 
coefficient (Kd) 
OECD 106 QSAR [19] 
x Includes ionisables 
and neutral 
organics 
 
x Bases: pKa>2, 
-1.66< logKow >7.03 
 
x Acids: pKa 0-12, -
2.19 < logKow > 
8.50 
1.) QSARs applied to realistic 
exposure scenario of 3 
compounds, results compared 
with monitoring data and output 
from conventional fugacity 
modelling [20]. 
 
2.) QSARs applied to 415 acids 
and 496 bases in a multimedia 
fate and effect model (USES-
LCA), indicated partitioning to 
solid-phase underestimated 
when ionisables not considered, 
(e.g. TGD method) [21]. 
x PECporewater is also calculated with this Kd estimation 
approach. 
 
x Further model refinement required for APIs 
specifically. 
 
x The multimedia fate model SimpleBox 4.0 has also 
been updated with this approach [22]. 
Sediment-water 
partition 
coefficient (Kd) 
OECD 106 (modified) 
OPPTS 835.110 QSAR [19]  N/A N/A 
x The water-soil Kd QSARs [19] has been suggested to 
use, nothing specifically developed for water-
sediment partitioning [20]. 
Sludge-water 
partition 
coefficient (Kd) 
    x  
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Table S12. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
Number Variable Experimental 
source 
Model/ 
predictive tool/  Applicability domain Experimental validation Method limitations/ Suggestions 
(7) 
Degradation 
DT50 (soil) OECD 307  (degradation test) BIOWIN 
x Able to predict not-
readily 
biodegradable 
substances with 
high accuracy in 
contrast to ready 
biodegradability 
[23]. 
1.) Compared API experimental 
anaerobic biodegradation with 
BIOWIN estimates, found a 
similar order in anaerobic 
biodegradability (n=4) [24]. 
 
2.)Validated the BIOWIN model 
using experimental data from 
110 compounds [23]. 
x Poor model predictions for chemicals that contain 
moieties or combinations of moieties that are not 
adequately represented in database to build models 
(e.g. pharmaceuticals).  
 
x Does not account for stereochemistry in predictions 
which is important for chiral molecules (e.g. 
pharmaceuticals) [25]. 
DT50 
(sediment) 
OECD 308 (309) 
(degradation test) BIOWIN   
x Can be applied for 
sediments, but not 
validated. 
N/A 
x Degradation in sediment will be subject variety of 
environmental conditions, for example experimental 
differences in degradation rates between moving and 
flat bed sediments observed [26]. 
 
x More work is needed to determine the 
appropriateness of BIOWIN for API degradation in 
sediment. 
(8) 
Application 
rate 
Application 
(kg/hectare 
(dry weight) 
per year) 
Localised application 
rate 
Default:  
x 5000 kg/ha·yr 
agricultural  
 
x 1000 kg/ha·yr 
grassland 
(dry weight) 
x Europe, however 
the Danish EPA 
suggest 6000 
kg/ha·yr (dry 
weight) application 
for risk 
assessment. 
N/A 
x The suitability of the defaults is dependent on the 
country-specific biosolid practices and legislation, for 
example the US applied 4.0x106 tons of dry weight 
biosolids, while Europe applied 2.39x106 tons in 2006 
[27]. 
 
x The magnitude and impact of the application rate of 
biosolids throughout the world in terms of APIs is 
largely unexplored. 
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Table S13. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
 
 
Number Variable Experimental 
source 
Model/ 
predictive tool 
Applicability 
domain 
Experimental 
validation Method limitations 
(9) 
Acute 
Fish LC50 OECD 203 
1.API specific 
ecotoxicity QSARs 
[28] 
 
2. ECOSAR [29] 
 
1. Applied QSAR to 
1267 APIs and the 
percent of APIs that fell 
in the applicability 
GRPDLQ$'ZDV 
 
2. ECOSAR 
-3 < LogKow < 5. 8 
Molecular weight <1000 
 
1. Relatively new 
QSARs, no external 
validation yet published. 
 
2. Limitations of 
ECOSAR demonstrated 
by many, notably 
Hulzebos and 
Posthumus (2003) [30]. 
 
 
x ECOSAR was developed with a small set of industrial 
chemicals with simple structures [31].  
 
x APIs have complex structures with multiple functional 
groups, which could have a specific mode of action 
[28,32]. 
 
x Experimental ecotoxicity data is limited. Invertebrate EC50 OECD 202 
Algae EC50 OECD 201 
Benthic Invertebrate 
EC50 OECD 218 Not yet developed N/A N/A 
x Unique exposure scenario where organisms could be 
exposed to water column, sediments and pore water. 
Earthworm LC50 
 
OECD 207 
1. Equilibrium 
partitioning concept 
applied to aquatic 
data for screening. 
 
2. Earthworm QSAR 
reported in Guo 
(2016) [33]. 
1. QSARs developed 
based on 11 compounds 
is valid for short-term 
toxicity of several 
chlorophenols, 
chlorobenzenes and 
chloroanilines [34]. 
2. None reported. 
1. API specific validation 
of this approach has not 
been attempted. 
 
2. None reported. 
 
x Equilibrium partitioning method may not be suitable 
for lipophilic compounds or substances with a specific 
mode of action (e.g. APIs) [34].  
 
x Does not consider the effects on soil organisms for 
chemicals that are adsorbed to soil particles and 
taken up by ingestion or contact with soil or sediment 
adsorbing chemicals (log Kow > than 3). 
Soil Invertebrate 
EC50 OECD 218 Not yet developed N/A N/A x Despite experimental field evidence of exposure, 
modelling consideration of this exposure pathway is 
largely unexplored for APIs. Terrestrial Plant 
EC50 OECD 208 Not  yet developed N/A N/A 
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Table S14. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
 
Number Variable Experimental 
source 
Model/ 
predictive tool 
Applicability 
domain 
Experimental 
validation Method limitations 
(10) 
Chronic 
Fish OECD 210 
1. ECOSAR: ChV 
(geometric mean of 
LOEC and NOEC) 
 
2. Claey (2013) [35]: 
QSARs for 
substances acting 
via nonpolar and 
polar narcosis. 
1. LogKow < 5.8, neutral 
organics. When chronic 
data is lacking acute to 
chronic ratios are used. 
 
2. Nonpolar narcosis: 
0.92 < logKow < 6.8 
Polar narcosis:  
6.83 < pKa <10.7 
1.46 < logKow < 5.76 
1. Validated for 23 
neutral organics (not 
APIs). Concluded when 
functional groups could 
have a specific mode of 
action (e.g. 
pharmaceuticals), 
ECOSAR not suitable 
and only when a 
compound is within the 
AD the QSAR is suitable 
[32]. 
 
2. Method has not been 
externally validated for 
APIs by others. 
x Chronic experimental data is rare putting a reliance 
on acute to chronic ratios for many structural classes 
in ECOSAR. 
 
x ECOSAR was creating using a limited number of 
compounds whose relevance to APIs is questioned 
[31]. 
 
x De Haas (2011) [32]  and Claeys (2013) [35], suggest 
chronic ECOSAR is not robust. 
 
Invertebrate OECD 211 
ECOSAR Chv 
 
1. LogKow < 5.8, 
neutral organics. When 
chronic data is lacking 
acute to chronic ratios 
are used. 
Not validated for APIs 
x Chronic experimental data for invertebrates and 
aquatic plants, validation and development has 
focused on fish. Algae OECD 221 
Benthic Invertebrate OECD 219 No QSAR for APIs developed N/A N/A 
x Despite experimental field evidence of exposure, 
modelling consideration of this exposure pathway is 
largely unexplored for APIs. 
(11) 
Assessment 
Factors 
Acute assessment 
factor (AF)  
Defaults suggested: 
EPA (1995) [36] 
EMEA 2006 [37] 
OECD 1992 [38] 
 
AF: No greater than 
1000, regardless of 
whether species is a 
standard test organism. 
 
AF: No less than 100 
even when acute 
LC(EC)50 is from most 
sensitive species. 
 
x Fish are most 
sensitive species 
and assessment 
factors applied to 
acute data may be 
acceptable when 
chronic data is 
missing (unless a 
mode of action 
concern is present) 
[39]. 
x Account for inter- and intra-species variability and 
extrapolate from lab to field or in silico prediction to 
field. 
 
x Derived from policy, assessment factors are arbitrary 
values which may have little scientific relevance, but 
reduce the likelihood of underestimating risk [40]. 
 
Chronic AF   ECHA (2008) [41] 
AF: 10 if ecotoxicity is 
available for 3 trophic 
levels. 
AF: 50 if ecotoxicity 
available for 2 trophic 
levels.  
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Table S15. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
 
  
 
 
Number Variable Experimental 
source
 
Model/ 
predictive tool 
Applicability 
domain 
Experimental 
validation Method limitations 
(12) 
Fish plasma 
concentration  
FPC
  
1. logPblood:water [42] 
 
2. BCF estimation 
(ionisables) [43] 
 
 
1. 0 < LogKow < 8 
 
2. Three equations 
covering acids, bases 
and neutral compounds: 
1< logKow <7 
Acid: -0.36 < pKa <10.6 
Base: 2 < pKa < 11.4 
 
 
1. Tested the read 
across hypothesis (using 
pH corrected logKow) 
for Fluoxetine, 
concluded powerful tool 
for risk assessment [44]. 
 
1b. Tested read across 
hypothesis for ibuprofen, 
provided evidence to 
support it [45]. 
 
2. Investigation of 
parameters used to 
model FPC, suggested 
approach (2) with 
logDow most robust 
[46]. 
 
x BCF method that considers ionisables preferred 
[43,46]. 
 
x Cmax values are more readily available[46]. 
 
 
x The read-across approach for risk assessment 
has limited validation [44,45]. 
(13) 
Internal 
concentration 
invertebrate 
IPC Method not yet 
suggested Not yet developed N/A N/A 
x An invertebrate internal concentration estimation 
method needs to be developed for invertebrates 
associated with the benthos and the water column. 
 
x A similar approach like the FPC could be possibility 
[47]. 
IPCbenthic Method not yet suggested Not yet developed N/A N/A 
(14) 
Therapeutic 
plasma 
concentration 
HtPC 
Cmax 
(peak plasma 
concentration) 
N/A N/A 
The area under the 
curve (AUC)
 
compared 
to Cmax  does not have a 
large impact of FPC 
results [46].  
x Highly dependent on the administered therapeutic 
dose/brand. 
 
x Lowest reported values taken to represent worst 
case. 
 
x Available in peer-reviewed pharmacokinetic literature 
or drug approval reports (EMA, FDA). 
AUCconc  
(area under the time-
concentration curve) 
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Table S16. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
 
 
Number Variable Experimental 
source 
Model/ 
predictive tool 
Applicability 
domain 
Experimental 
validation Method limitations 
(15) 
Bioconcentration 
factors 
(BCF) 
Fish BCF  OECD 305 1. See FPC  2. QSAR [48]  
1. See FPC 
2. 1< LogKow <10 
 
1. Not validated 
specifically for 
pharmaceuticals. 
 
2. Meylan evaluated 694 
logBCF/logKow data 
values 610 non-ionic 
and 84 ionic covering a 
logKow range of 3.98-
13.98 to derive QSARs. 
 
x Linear and parabolic approaches to cover 
logKow 2- 10 suggested [48], LogKow >10 BCFs 
should be treated as qualitative.  
 
x These models are not applicable to ionisable 
compounds [49].  
 
x Neither approach validated explicitly for 
pharmaceuticals. 
Invertebrate BCF  BCF minimised design [50] Not yet developed N/A N/A 
x Uptake of APIs in invertebrate has been shown 
[51,52], but a suitable predictive model for neutrals 
and ionisables has yet to be developed. 
x OECD 305 methods may be inappropriate for 
invertebrates. 
Benthic Invertebrate 
BCF  
Test method not yet 
suggested Not yet developed N/A N/A 
x QSARs are only available to predict fish and algal 
BCFs. 
 
x Field studies demonstrated pharmaceutical 
accumulation in benthic invertebrates [53,54]. 
Earthworm BCF 
 
OECD 317 QSAR [55,56]  0 < logKow < 8 
BCF/BAF estimation 
approach has been 
validated, but not for 
pharmaceuticals 
specifically [57]. 
x Current predictive method not suitable for ionisable 
organic chemicals and poor performance for 
chemicals of moderate to high hydrophobicity [11,55]. 
Plant BCF 
 
Test method not yet 
suggested Not yet developed N/A N/A 
x Pharmaceutical uptake has been demonstrated in the 
lab and in the field [58,59]. 
 
x Developing a predictive tool for this uptake pathway 
will be especially important as human intake 
stemming from biosolid use and reclaimed 
wastewater on cropland has been demonstrated [60].  
(16) 
NOAEL Mammal 
Clinical and pre-
clinical data Toxicity 
studies ±repeated-
dose toxicity (NOAEL 
28, 90 day) or chronic 
study 
Assessment factor : 
NOECmammal, 28 
days=300 
90 days =90 
Chronic=30 
N/A N/A 
x Available as pre-clinical data. 
 
x Convert NOAEL to NOEC but not appropriate to 
extrapolate LC50 tests to derive NOEC unlike birds 
[11]. 
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Table S17. (continued) Parameters needed to estimate environmental active pharmaceutical ingredient (API) exposure and effects in multiple compartments. Summarised 
in Table 3 of the main text. Numbers refer to the framework presented in Figure 4-6. Default refers to suggestions from the EMA (2006) guidelines. 
(17) 
NOEC Bird 
OECD 205, 206, 223 
(1984hr, LC50 acute 
avian bird study) 
Assessment factor: 
LC50 bird = 3000 
NOEC bird (chronic) 
=30 
Extrapolate toxicity tests 
to get conversion to 
NOEC 
 
x Extrapolate toxicity tests (LC50) for conversion to 
NOEC (OECD 205, 206) 
(18) 
Multiple prey 
types 
Uncertainty factors Not yet derived N/A N/A N/A 
x Applying an uncertainty factor to the feeding habit. 
x Uncertainty in uptake across prey species, e.g. 
different type of plants invertebrates consume. 
(19) 
Feeding 
behaviour 
Dietary inputs Not yet derived N/A N/A N/A 
x Assessment of the diet for the species in question is 
(i.e. how much fish, plant, worm does it generally 
consume to calculate the exposure). 
(20) 
Acceptable daily 
intake  
ADI Mammalian chronic toxicity studies  
 
1. Calculate from 
NOAEL from most 
sensitive species in 
most sensitive 
test.[61] (EQ. SX) 
 
2. Calculate ADI 
from LOEL and 
series of uncertainty 
factors.[62] (EQN. 
SX) 
N/A N/A 
x This is based on arbitrary uncertainty factors to 
ensure conservative risk assessment, which may be 
modified when adequate human data or comparative 
pharmacokinetic or toxicodynamic data are 
available.[61] 
(21) 
Human diet Agricultural practice Not yet derived N/A N/A N/A 
x Human exposure has only included contamination of 
fish or drinking water.[62] 
x Regions which rely on application of biosolids or 
wastewater reclamation for agriculture will need 
combination of PICplant and an assessment factor to 
be applied. 
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